Most Recent
‘Substantial industrial theft’: Hytera to face damages for stealing Motorola’s source code
A judge has found Shenzhen-based based radio manufacturer Hytera engaged in "substantial industrial theft" by appropriating Motorola's source code for its digital mobile radios and should be on the hook for additional damages for "flagrantly" infringing Motorola's copyright.
Novartis, Pharmacor resolve suit over Gilenya patents
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant's patents for blockbuster MS drug Gilenya.
Defamation, class action barristers among 20 new silks
Twenty barristers have risen to the ranks of senior counsel in New South Wales, including a veteran defamation barrister, two counsel with class action expertise and part of the team that saw ASIC's claims against two Rio Tinto executives dropped.
Full Court upholds validity of Pfizer’s Dynastat patent
A judge has thrown out competing appeals of a decision finding Pfizer's patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Bangkok Broadcasting settles ‘7’ trade mark stoush with Seven Network
Bangkok Broadcasting and Seven Networks have settled two lawsuits over the Thai broadcaster's registration of '7' marks in Australia.
Pfizer sues drug companies over Enbrel biosimilar
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
Novartis can’t appeal loss of experts in MS drug patent feud with Pharmacor
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
Novartis challenges loss of experts in spat with Pharmacor over generic Gilenya
Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.
Judge tosses Novartis experts out of ‘hot tub’ in MS drug patent dispute
A judge has slammed Novartis for putting forward four "overlapping" experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a "hot tub".